Inovio Pharmaceuticals Stock Tumbles 5% After Earnings — Most Of Its Wider Loss Was Non-Cash
Launch preparations increased expenses, while a completed offering added approximately $80.5 million to its funding.
Inovio Pharmaceuticals, which develops DNA medicines, fell 4.8% to $1.38 in Wednesday trading, as of 10:30 AM ET, erasing $8 million in market value. The decline followed its earnings report in an SEC filing Tuesday, with non-cash warrant revaluations accounting for most of the wider quarterly loss.
Warrant Revaluations Drove The Wider Loss
Inovio Pharmaceuticals' quarterly net loss reached $49.2 million, compared with $45.5 million. Non-cash adjustments to warrant valuations increased to $26.9 million from $22.5 million.
Selling and administrative expenses increased, too. The company attributed that increase to preparations for VOCERYQ's launch.
On Tuesday's earnings call, management said the commercial launch depends on concentrated treatment centers and insurer coverage. The company projects that its funding, including approximately $80.5 million from a completed offering, will sustain operations into late fourth quarter 2027.
A Launch Ahead, Research Behind It
Inovio Pharmaceuticals develops treatments for diseases linked to human papillomavirus, or HPV, cancer and infectious diseases. Its DNA medicines instruct cells to produce specific proteins; CELLECTRA devices help deliver the medicines into cells using brief electrical pulses.
Its lead candidate, INO-3107, targets recurrent respiratory papillomatosis, a rare disease that produces airway tumors. Other candidates target throat cancer and other cancers.
In its annual report for 2025, the company described all its candidates as still in research and development. It had earned no product-sales revenue, instead drawing revenue from licensing, milestone payments and collaborative research agreements and contracts.
The Monthly Rebound Meets Another Decline
Wednesday's slide was on pace to become the stock's fifth decline of 3% or more this month. Inovio Pharmaceuticals' market value was about $152 million in Wednesday trading.
The stock's recent recovery had left it behind the broader market. At Tuesday's close, shares were down 17% for the year, compared with a 10% gain for the S&P 500 over the same span. Shares had gained 26% over the previous month.
Inovio Pharmaceuticals is scheduled to present next Wednesday at the Jefferies Global Healthcare Conference in London.
Sources
- 2 life sciences companies raise $86M each in public stock sales - Philadelphia Business Journal — bizjournals.com
- Inovio: Q3 Earnings Snapshot | wfaa.com — Associated Press
- Inovio: Q3 Earnings Snapshot | wusa9.com — Associated Press
- Inovio: Q3 Earnings Snapshot | 11alive.com — Associated Press
- INOVIO to Participate in Upcoming Investor Conferences — prnewswire.com
- The company's filing (Inovio Pharmaceuticals) — SEC filing
- Inovio Pharmaceuticals — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR
